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Adrenocortical carcinoma (ACC) is a rare malignancy that is generally associated with a poor prognosis
whose existence dictates the management of incidental renal masses. We report a case of ACC diagnosed
and treated at its apparent inception in a patient undergoing close surveillance imaging of a prior ma-
lignancy. Despite timely detection and resection of a localized ACC this patient rapidly progressed to
systemic disease. This case highlights the rapid growth kinetics of ACC and puts into perspective the
challenges associated with the established treatment paradigm for patients diagnosed with an adrenal
mass.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Adrenocortical carcinoma (ACC) is an uncommon malignancy
with an estimated incidence of 0.5e2 per million.1 Meanwhile,
benign adrenal masses are present in >5% of the elderly popula-
tion.2 Despite rarity of ACC, the possibility of its existence dictates
the management of incidentally discovered adrenal lesions. Indeed,
indications for surgical resection such as adrenal mass growth
greater than 1 cm and tumor size greater than 4 cm aim to achieve
ACC cure prior to metastatic progression.3 Here, we present a case
of a 3.8 cm ACC that was diagnosed at its apparent inception in a
patient with lung cancer who underwent frequent surveillance
cross-sectional imaging, and despite timely treatment, rapidly
progressed to systemic disease.tment of Surgery, Fox Chase
ottman Avenue, Philadelphia,
tikov).
Inc. This is an open access article uCase presentation
A 73-year-old woman with hypertension and history of non-
small cell lung adenocarcinoma (T1bN0M0, Stage I), resected
2.5 years previously, was referred to the urologic oncology clinic
with a rapidly growing, asymptomatic left adrenal mass. The initial
concern was for a solitary metastasis of lung cancer to the adrenal
gland. At the time of referral, the left adrenal mass measured
2.3  3 cm and exhibited attenuation of 35 HU on non-contrast
imaging (Fig. 1). PET-CT demonstrated intense FDG avidity (11.3
SUV) within the corresponding lesion (Fig. 2). Otherwise, imaging
of the brain, thorax, abdomen and pelvis were unremarkable. In
retrospect, an adrenal mass was present on the patient’s previous
scan, 6-months prior, and measured 1.1 cm, demonstrating lipid-
poor characteristics (Fig. 1). This same mass was detected at
initial presentation, 3 years prior, was not FDG avid, and remained
stable in size on numerous 6-month interval surveillance imaging
studies. Adrenal metabolic work-up at the time of referral was
signiﬁcant for inappropriate suppression of serum cortisol on
low-dose dexamethasone suppression test (8.74 mcg/dL,
normal < 5 mcg/dL). Plasma free metanephrines, serum aldoste-
rone, and adrenal sex steroid testing with dehydroepiandrosteronender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Computed Tomography (CT) imaging of adrenal mass. (a) Axial contrast-enhanced image depicting 1.1 cm adrenal mass that had remained stable for several years on
surveillance imaging. (bec) Axial and coronal CT imaging at time of referral demonstrating a 2.3  3.3 cm lipid poor adrenal mass (non-contrast CT attenuation 35 HU).
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testosterone and 17-beta estradiol were unremarkable. The patient
underwent an uneventful laparoscopic left adrenalectomy within
4 weeks of being seen in consultation. Pathologic examination
revealed a high grade 3.8 cm adrenocortical carcinoma with
venous invasion and negative surgical margins. As per the standard
of care, the patient received adjuvant mitotane. After two months
of adjuvant therapy, the patient was found to have progressive
disease with extensive metastatic disease to the liver detected on
cross-sectional imaging (Fig. 3) and conﬁrmed on ﬁne needle
aspiration biopsy. The patient subsequently received two cycles of
etoposide, cisplatin, doxorubicin (ECD) systemic chemotherapy.
Due to rapid disease progression, treatment was suspended after
two cycles, and the patient expired 10 months following
adrenalectomy.Figure 2. Positron Emission Tomography/CT imaging displaying avid FDG uptake (11.3
SUV) in the adrenal mass (arrows). No other pathologic FDG uptake was noted else-
where in the body.Discussion
We report a unique case of an ACC that was detected and
removed at its apparent inception. Although a stable w1 cm mass
was present on the adrenal gland of our patient for several years,
transformation of this lesion into a rapidly growing malignancy vs.
development of a new adjacent aggressive lesion was noted on
biannual cross-sectional imaging. Despite timely surgical inter-
vention for clinically localized disease that measured <4 cm at
resection, this patient’s malignancy exhibited rapid systemic pro-
gression. This case underscores breakneck ACC disease progression
kinetics and the short, and arguably in some cases non-existent,
window of therapeutic opportunity in patients with this malig-
nancy. Indeed, our case dovetails with previous reports from
administrative datasets that have documented lack of both stage
migration and absence of improvement in survival for patients withACC over the last several decades despite advent of ubiquitous
cross-sectional imaging.4
Since oncologic risks currently drive management decisions in
patients with adrenalmass, this case highlights shortcomings of the
current treatment paradigm.5 Indeed, thousands of patients are
annually subjected to risks of adrenalectomy,6 based on current
management guidelines, in order to potentially affect outcomes of
less than 100 patients who present each year with small (<6 cm)
ACC in the United States.7 This case highlights that favorable
oncologic outcomes are elusive even in patients who receive timely
surgical extirpation for localized ACC.
Figure 3. Axial and coronal CT imaging demonstrates diffuse metastatic disease within the liver parenchyma (arrows).
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This is a rare case where inception of an adrenal cortical carci-
noma was incidentally witnessed during close radiographic sur-
veillance of another malignancy. Despite timely resection, this
patient rapidly progressed to systemic disease and died from ACC
within 1 year of surgery. This report underscores a need to better
calibrate and balance risks of delaying ACC treatment against the
burden of overtreatment of patients with benign adrenal mass.
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